Migraine - FOI Response Register

1. Please provide the number of migraine patients treated in the last 4 months with:

•     Atogepant (Aquipta)

 0

•     Erenumab (Aimovig)

 <5

•     Eptinezumab (Vyepti)

0

•     Fremanezumab (Ajovy)

<5

•     Galcanezumab (Emgality)

0

•     Rimegepant (Vydura)

None treated with prophylactic dose

•     Botulinum Toxin (i.e., Botox, Dysport, Xeomin)

0

Where we have provided <5 answers this is because NHS Shetland considers that providing more specific information carries a high risk of identifying (or disclosing information about)

individual patients. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s

38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.

2. How many patients have you treated in the last 4 months for acute migraine with:

•     Rimegepant (Vydura)

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested.

3. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

No